Bicara Therapeutics Inc. Common Stock
NASDAQ Global MarketTotal Valuation
Bicara Therapeutics Inc. Common Stock carries a market capitalization of 1.16B, placing it among publicly traded companies globally. Its enterprise value stands at 1.45B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 1.16B |
| Enterprise Value | 1.45B |
Share Statistics
Bicara Therapeutics Inc. Common Stock currently has 65.55M shares outstanding.
| Shares Outstanding | 65.55M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | 4.15 |
| P/TBV Ratio | 4.15 |
| P/FCF Ratio | -13.16 |
| P/OCF Ratio | -13.12 |
Financial Position
Bicara Therapeutics Inc. Common Stock maintains a current ratio of 11.59, meaning it holds 11.6x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 11.59 |
| Quick Ratio | 11.44 |
| Debt / Equity | 0.25 |
| Debt / EBITDA | -0.01 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | -41.01 |
| Return on Assets (ROA) | -38.38 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Taxes
| Income Tax | 206,000.00 |
| Effective Tax Rate | N/A |
Stock Price Statistics
Bicara Therapeutics Inc. Common Stock's stock has gained approximately 7.44157% over the past 52 weeks. The 50-day moving average sits at 21.54, while the 200-day moving average is 21.30.
| Beta (5Y) | N/A |
| 52-Week Price Change | 7.44157% |
| 50-Day Moving Average | 21.54 |
| 200-Day Moving Average | 21.30 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -201.84M, while operating income came in at -201.99M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -201.99M |
| Pretax Income | -185.16M |
| Net Income | -185.36M |
| EBITDA | -201.84M |
| EBIT | -201.99M |
| Earnings Per Share (EPS) | -3.11 |
Balance Sheet
Bicara Therapeutics Inc. Common Stock holds 497.26M in cash and equivalents against 1.16M in total debt, resulting in a net debt position of -96.60M. Total book value stands at 468.77M, with working capital of 460.35M providing operational flexibility.
| Cash & Cash Equivalents | 497.26M |
| Total Debt | 1.16M |
| Net Debt | -96.60M |
| Equity (Book Value) | 468.77M |
| Book Value Per Share | 7.15 |
| Working Capital | 460.35M |
Cash Flow
Bicara Therapeutics Inc. Common Stock produced -134.85M in operating cash flow over the past twelve months. After subtracting -400,000.00 in capital expenditures, free cash flow totaled -135.25M - equivalent to -2.27 per share.
| Operating Cash Flow | -134.85M |
| Capital Expenditures | -400,000.00 |
| Free Cash Flow | -135.25M |
| FCF Per Share | -2.27 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -10.14 |
| FCF Yield | -7.60 |
Scores
Bicara Therapeutics Inc. Common Stock posts an Altman Z-Score of 25.35, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 25.35 |